Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Current Assets (2021 - 2026)

bioAffinity Technologies has reported Current Assets over the past 6 years, most recently at $4.3 million for Q1 2026.

  • Quarterly Current Assets rose 132.94% to $4.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Mar 2026, up 132.94% year-over-year, with the annual reading at $7.6 million for FY2025, 180.7% up from the prior year.
  • Current Assets was $4.3 million for Q1 2026 at bioAffinity Technologies, down from $7.6 million in the prior quarter.
  • Over five years, Current Assets peaked at $14.1 million in Q3 2022 and troughed at $1.7 million in Q2 2025.
  • The 5-year median for Current Assets is $4.3 million (2026), against an average of $6.1 million.
  • Year-over-year, Current Assets surged 731.69% in 2022 and then crashed 69.05% in 2024.
  • A 5-year view of Current Assets shows it stood at $12.0 million in 2022, then plummeted by 66.79% to $4.0 million in 2023, then tumbled by 32.16% to $2.7 million in 2024, then skyrocketed by 180.7% to $7.6 million in 2025, then tumbled by 42.61% to $4.3 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Current Assets are $4.3 million (Q1 2026), $7.6 million (Q4 2025), and $8.6 million (Q3 2025).